文献速递皮肤肿瘤

AI辅助线场共聚焦光学相干断层扫描检测亚临床基底细胞癌

AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma.
PubMed 文献 · JAMA Dermatol · 2026-01-01

这项前瞻性横断面可行性研究在德国埃尔朗根大学医院皮肤科纳入150例至少有两个基底细胞癌(BCC)危险因素的患者,对无宏观可疑病变的面部皮肤行AI辅助线场共聚焦光学相干断层扫描(LC-OCT)系统筛查。在14例患者中发现17个亚临床BCC,AI辅助LC-OCT诊断BCC的阳性预测值(PPV)为83.3%(95%CI 58.6%-96.4%),敏感性分析中PPV为94.4%(95%CI 72.7%-99.9%)。提示AI辅助LC-OCT用于高危人群亚临床BCC筛查可行,但需进一步研究评估敏感性和成本效益。

要点

  • 高危人群面部无宏观可疑病变皮肤行AI辅助LC-OCT可检出亚临床BCC。
  • AI辅助LC-OCT诊断BCC的PPV为83.3%(95%CI 58.6%-96.4%)。
  • 亚型分类在15例组织学确诊者中准确13例(86.7%)。

核心结论

  • 在高危人群中,AI辅助LC-OCT系统筛查可能是一种在临床前期阶段检出BCC的可行方法。
  • 在常规推荐前,尚需进一步前瞻性研究评估该方法的敏感性、成本效益及早期检出是否转化为实际临床获益。

研究设计与样本

  • 前瞻性横断面可行性研究,2025年4月至2025年10月在德国埃尔朗根大学医院皮肤科开展。
  • 连续纳入接受住院治疗且至少有两个已确立BCC危险因素的患者。
  • 排除宏观上可疑为BCC的病变后,对无异常表现的面部皮肤行AI辅助LC-OCT系统检查。
  • 共纳入150例患者,平均(SD)年龄72.9(10.3)岁,女性57例(38.0%),男性93例(62.0%)。

主要发现

  • 在14例患者(9.3%)中发现17个亚临床BCC。
  • AI辅助LC-OCT诊断为BCC的18个病变中,15个经组织学确诊,PPV为83.3%(95%CI 58.6%-96.4%)。
  • 1个病变为假阳性(光化性角化病),2例患者拒绝活检。
  • 敏感性分析纳入2个未活检但经专家分析确认的病变后,PPV为94.4%(95%CI 72.7%-99.9%)。
  • BCC亚型分布为浅表型13例(76.5%)、结节型3例(17.6%)、浸润型1例(5.9%);亚型分类在15例组织学确诊者中准确13例(86.7% [95%CI 59.5%-98.3%])。

临床怎么用

  • 对于有至少两个BCC危险因素的高危患者,可考虑使用AI辅助LC-OCT对无宏观可疑病变的面部皮肤进行系统筛查以检出亚临床BCC。
  • 目前证据尚不足以推荐将AI辅助LC-OCT筛查常规用于临床实践,需进一步评估其敏感性、成本效益和临床获益。

局限性

  • 本研究为横断面可行性研究,样本量有限。
  • 2例患者拒绝活检,相关病变未获组织学确诊。
  • 未评估筛查方法的敏感性。
  • 未评估成本效益及早期检出是否转化为实际临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Basal cell carcinoma (BCC) is the most common type of skin cancer worldwide. Particularly on the face, its locally destructive growth leads to functional and aesthetic impairment. Early diagnosis enables less invasive treatment. Line-field confocal optical coherence tomography (LC-OCT) is an effective noninvasive imaging method for the diagnosis of BCC. OBJECTIVES: To investigate whether LC-OCT paired with artificial intelligence (AI)-assisted image recognition can identify subclinical BCCs through systematic screening of inconspicuous facial skin in patients at high risk of developing BCC. DESIGN, SETTING, AND PARTICIPANTS: This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025 at the Department of Dermatology, Uniklinikum Erlangen, in Erlangen, Germany. Consecutive patients receiving inpatient care who had at least 2 established BCC risk factors were enrolled in the study. EXPOSURE: After the exclusion of lesions macroscopically suggestive of BCC, inconspicuous facial skin was systematically examined using AI-assisted LC-OCT. MAIN OUTCOME AND MEASURE: The prespecified main outcome was positive predictive value (PPV) of AI-assisted LC-OCT for histologically confirmed subclinical BCC. RESULTS: Among 150 patients (mean [SD] age, 72.9 [10.3] years; 57 [38.0%] female; 93 [62.0%] male), 17 subclinical BCCs were identified in 14 patients (9.3%). Of 18 lesions diagnosed as BCC with AI-assisted LC-OCT, 15 were histologically confirmed, corresponding to a PPV of 83.3% (95% CI, 58.6%-96.4%). One lesion had a false-positive result (actinic keratosis); 2 patients declined biopsy. In a sensitivity analysis including the 2 nonbiopsied lesions that were confirmed with expert analysis, PPV was 94.4% (95% CI, 72.7%-99.9%). The distribution of BCC subtypes included 13 cases of superficial BCCs (76.5%), followed by 3 cases of nodular BCCs (17.6%), and 1 case of infiltrative BCC (5.9%). Subtype classification was accurate in 13 of 15 histologically confirmed cases (86.7% [95% CI, 59.5%-98.3%]). CONCLUSIONS AND RELEVANCE: In this cross-sectional feasibility study, the findings suggest that systematic screening with AI-assisted LC-OCT may be a feasible approach for BCC detection at a preclinical stage in populations at high risk for BCC. Further prospective studies are needed to assess the sensitivity and cost-effectiveness of this method, and whether early detection translates to tangible clinical benefit before implementation in routine care can be recommended.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Ronicke M, Dürr L, Höner MW, et al. AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma. JAMA Dermatol. 2026. PMID: 42616540. doi:10.1001/jamadermatol.2026.2992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。